BLAVIAL
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HUMIRA (adalimumab) is a fully human monoclonal antibody that inhibits tumor necrosis factor (TNF)-alpha, a key driver of inflammation. It is indicated for multiple autoimmune and inflammatory conditions including rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. HUMIRA has become one of the most widely prescribed biologics globally since its 2002 approval.
$0.258BPart D
LOE ApproachingDeclining
As HUMIRA approaches loss of exclusivity with high competitive pressure (30 competitors identified), brand teams face significant headcount transitions and a shift from growth initiatives to lifecycle defense and retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial
Started Sep 2026
160 enrolled
Juvenile Idiopathic Arthritis Associated UveitisUveitis, Anterior
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
Started Aug 2026
30 enrolled
Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease
A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
Started Jul 2026
30 enrolled
Adult Non-infectious Uveitis
A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
Started May 2026
30 enrolled
Severe Plaque Psoriasis in Chinese Children
A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects
Started Mar 2025
444 enrolled
Healthy Adult Male
Worked on HUMIRA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.